

Identification of new alpha-synuclein fibrillogenesis inhibitor using in silico structure-based virtual screening

Mehdi Sahihi, Fatma Gaci, Isabelle Navizet

▶ To cite this version:

Mehdi Sahihi, Fatma Gaci, Isabelle Navizet. Identification of new alpha-synuclein fibrillogenesis inhibitor using in silico structure-based virtual screening. Journal of Molecular Graphics and Modelling, 2021, 108, pp.108010. 10.1016/j.jmgm.2021.108010. hal-03705000


HAL Id: hal-03705000 https://hal.science/hal-03705000v1

Submitted on 26 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Identification of new alpha-synuclein fibrillogenesis inhibitor
2	using in silico structure-based virtual screening
3	Mehdi Sahihi ^{1,2,*} , Fatma Gaci ² , Isabelle Navizet ²
4	¹ Roberval Laboratory, Université de Technologie de Compiègne, Alliance Sorbonne Université,
5	Compiègne, France
6	² MSME, Univ Gustave Eiffel, CNRS UMR 8208, Univ Paris Est Creteil,
7	F-77454 Marne-la-Vallée, France
8	
9	
10	
11	
12	
13	
14	*Corresponding author:
15	Mehdi Sahihi
16	<i>Tel:</i> +33 (0) 6 24 67 38 28
17	Fax: +33 (0) 1 60 95 77 99
18	E-mail : <u>mehdi.sahihi@gmail.com</u>
19	

Graphical abstract:




1 Highlights:

2	•	Similar compounds to DHM were selected from PubChem library using VS method.
3	•	α SN monomer binding affinity of the filtered molecules were analyzed in details.
4	•	The best compound was selected as α SN aggregation Inhibitor for further analysis.
5	•	MD simulation study showed that the inhibitor weakens the structure of α SN trimer.
6		

1 Abstract

Abnormal aggregation and accumulation of alpha-synuclein (α SN) in existing neurons is 2 3 associated with Parkinson's disease (PD) as one of the age-related neurodegenerative disorders. 4 Inhibition of aSN fibrillogenesis could be considered as a solution for PD diseases treatment. Here, virtual screening (VS) approach was used to investigate available ligands in PubChem library with 5 6 structural similarity with Dihydromyricetin (DHM) (as a recently introduced suitable candidate 7 for designing of novel antiPD drugs) against aggregation of aSN chains. Primary screening identified 314 promising molecules for aSN monomer, which were further analyzed in details by 8 9 their binding energy and binding modes through molecular docking method. Evidently, the compound with PubChem ID of 100968625 displayed the lowest free binding energy with $\Delta G^0 =$ 10 -7.1 kcal.mol⁻¹ and was selected for further analysis using molecular dynamics (MD) simulation 11 method. Analysis of MD trajectories showed that molecules of the selected ligand interact with 12 aSN trimer via H-bond interaction and destabilize the compact structure of aSN trimer. Further, 13 prompt in vivo testing to validate the antiPD inhibition efficiency by this molecule can save lives. 14

- 15
- 16
- 17
- 18
- 19
- 20



One of the age-related neurodegenerative disorders is Parkinson's disease (PD) of which the 2 3 frequency increases with the increase in age. About 2–3% of people over 65 years old worldwide 4 suffer from the disease [1]. This disease characterized by occurrence of Lewy bodies (LBs) which is formed by abnormal aggregation and accumulation of alpha-synuclein (α SN) in existing neurons 5 6 [2, 3]. aSN is a 140 amino acids protein (molecular weight of about 14 kDa) with significant 7 conformational flexibility that can adopt a wide range of structural conformations such as fibrils 8 and oligomers [4, 5]. The native structure of α SN is not still exactly defined and has been described 9 as intrinsically disordered protein (IDP) [6, 7], helical [8, 9], or a mixture of both [10]. While the 10 function of α SN is unclear, it is highly enriched in neurons, where it is present in the presynaptic cleft as well as mitochondrial membranes. As for Alzheimer's disease (AD), for which certain 11 oligomers of the amyloidogenic protein are toxic, the initiation of formation of α SN aggregate is 12 suspected to be a key step in PD disease formation [11]. The cytotoxic effect of these aggregates 13 14 could be because of their effect on lipid membrane permeabilisation, mitochondrial damage and oxidative stress [12]. Also, recent experimental studies have shown that the injection of α SN 15 aggregates in animal's brain can stimulate their prion-like spread in other brain regions [13]. Most 16 17 of the available drugs for PD are chemicals acting as a prodrug that will be converted in dopamine in the brain [14, 15] or are dopamine agonists inhibiting the enzymes responsible of dopamine 18 19 metabolism [16, 17]. Both of these sorts of medicines cause unwanted side effects such as headaches, nausea, somnolence and so on [17]. Hence, inhibition of aSN fibrillogenesis and 20 disaggregation of aSN fibrils by therapeutic medications could provide a more significant 21 neuroprotective effect against PD diseases [18, 19]. Nowadays, finding of compounds that can 22 work as robust inhibitors of α SN fibrillogenesis remains an important challenge. Given the 23

enormous set of existing compounds, it is impossible to perform experimental screening of all
 available databases in a reasonable timeframe. Advances in computational chemistry provide new
 opportunities to steer experiments with realistic simulations on how the available compounds may
 be manipulated to introduce new effective inhibitor for αSN aggregation at minimum cost.

Virtual screening (VS) is known as one of the effective methods to recognize novel bioactive compounds and is being used in many drug discovery and development strategies at the moment. In this method, the chemical entities of big libraries are rapidly screened to achieve structures with better ligand-receptor interaction pattern. In most of the VS strategies docking methods are applied on the large databases [20, 21].

Flavonoids are one of the large class of natural compounds that are mainly found in plant-derived 10 materials and display antioxidant [22, 23] and anti-carcinogenic activities [24-26]. The ability of 11 flavonoids to bind to carrier proteins [27-29] as well as their effects against cancer [30] and 12 nicotine-induced oxidative stress [31] have been validated by a large number of investigations. 13 Dihydromyricetin (DHM; Figure S1) is a flavonoid compound isolated from Ampelopsis 14 grossedentata (a traditional southern Chinese herb), that has several physiological and 15 16 pharmacological effects [32]. Especially, DHM showed neuroprotective against oxidative stress and valuable effects in neurodegenerative diseases [33]. Recently, Jia et. al. found that DHM could 17 inhibit aSN fibrillogenesis and destabilize mature aSN fibrils in a dose-dependent manner [34]. 18 19 Their findings suggested that DHM has a great potential to be developed into a new aggregation inhibitor for aSN. Since DHM inhibits aSN fibrillogenesis and destabilizes mature aSN fibrils, its 20 derivatives would be suitable candidates for designing of novel antiPD drugs with inhibitory 21 22 effects on aggregation of α SN.

Therefore, in the present work the following computational studies have been done to design new 1 2 α SN aggregation inhibitor using VS strategy:

- 3 1- More than 8600 compounds with similar chemical structure to DHM were chosen from 4 PubChem free database [35].
- 2- These compounds have been filtered on basis of Lipinski's "Rule of five" and topological 5 6 polar surface area (TPSA)
- 7 3- The binding properties of the 314 remained compounds with αSN monomer have been 8 investigated using molecular docking tools.
- 9 4- By considering the results of the VS part, the compound with lowest binding energy was chosen to perform a 100 ns molecular dynamics (MD) simulation of its complex with a 10 α SN trimer to investigate its effect as potential inhibitor for α SN aggregation. 11
- 12
- 13

2. Computational procedures

14 2.1.Building a library of the drug-like compounds

Structure based VS is one of the common techniques being used in primary phases of drug design, 15 16 discovery and development at pharmaceutical companies and academic groups [36]. To build a library of candidate molecules, the structure of DHM was selected as template and similar 17 structures were saved from PubChem free database. The physicochemical characteristics of small 18 19 molecular drugs have an important effect on their Blood-Brain barrier (BBB) permeability. Based on Lipinski's rule of five, a small molecular drug must have less than 5 H-bond donors, less than 20 21 10 H-bond acceptors, be smaller than 500 Da of molecular weight, and its calculated octanol-water 22 partition coefficient (log P) should be less than 5 to have an appropriate BBB permeability [37]. The log P value of a compound is the logarithm of its partition coefficient between n-octanol and 23

water (log (c_{octanol}/c_{water})) and is an extent of the compound's hydrophilicity. The ideal range for
BBB permeability has been found to be 1.5-2.5 [38]. We used the Lipinski's rule of five from the
filters available in the PubChem database to select the candidate molecules for the VS. Then, the
topological polar surface area (TPSA; as a commonly used medicinal chemistry metric for the
optimization of a drug's ability to permeate cells) was calculated using Molinspiration webserver
(www.molinspiration.com). Therefore, only compounds with TPSA between 20 and 130 Å² were
kept in the VS database [39]. DHM and 314 other ligands met the criteria.

8 *2.2.Molecular Docking*

The experimental structure of αSN saved from PDB (PDB ID: 1XQ8) database [40]. This structure 9 10 has been obtained by average structure criteria using solution NMR method. The water molecules of the .pdb file were removed and hydrogen atoms, charges, standard bond orders and the missing 11 residues were added using Build/Check/Repair model wizard in WHAT IF web interface [41]. 12 Minimization was carried out up to 500 steps by steepest descent method using GROMACS 2018 13 package [42] with GROMOS96 53A6 force field [43]. The structures of the obtained drug-like 14 compounds were saved in .sdf format and converted to .pdbqt format using PyRx 0.8 software as 15 16 input files for VS [44]. The chemical structure of DHM and the 314 other ligands (obtained after filtration by Lipinski's rule of five and TPSA calculations) were geometry optimized by AM1 semi 17 empirical level of theory using Gaussian 09 quantum chemistry package [45] and are represented 18 19 in Table S1. The blind molecular docking of DHM to aSN monomer was carried out using AutoDock Vina [46] which is an academic-free molecular docking (and virtual screening) software 20 21 and works based on empirical scoring functions. The molecular docking was done based on a semi-22 flexible docking mechanism with a rigid receptor and flexible ligand. The default parameters were assigned for molecular docking calculations and the pose with the lowest binding energy was 23

chosen as final result. For the other compounds obtained from PubChem database, the center of
 the docking box was set in the center of the DHM binding site and the same procedure was done.

3 *2.3.MD simulation*

The initial structure of aSN trimer used in the MD simulation has been obtained from its available 4 amyloid fibril structure determined by cryo-electron microscopy (PDB ID: 6A6B [47]). All MD 5 simulations were performed using the GROMACS 2018 package [42] with GROMOS96 53A6 6 force field [43]. The force field parameters of the selected ligand (the small molecule with the most 7 8 negative binding energy to aSN monomer) were obtained from prodrg web server [48] and Lemkul's method [49] was used to correct the atomic partial charges. The α SN trimer was put 9 10 in a cubic box with periodic boundary conditions (PBC) in three directions. The protein trimer was placed in the center of the box and the minimum distance between solute surface and the box was 11 set to 1.0 nm. Ten molecules of the selected ligand were randomly placed around the aSN trimer. 12 Then, the box was filled with SPC water molecules [50] and the system was neutralized by 13 replacing six water molecules with Chloride ions (Cl⁻). In parallel, a system of α SN trimer without 14 the ligand molecules was also prepared. The systems were energy minimized using 50000 steps of 15 the steepest descent method and were equilibrated for 1 ns in NVT followed by 1 ns in NPT 16 ensembles. Finally, a 100 ns MD simulation was carried out at 1 bar and 300 K for each system. 17 Berendsen thermostat [51] Parrinello–Rahman barostat [52, 53] and 1 nm cutoff for van der Walls 18 19 (vdW) and Coulomb interactions were applied. Also, the long-range electrostatics were considered by particle mesh Ewald (PME) method [54, 55] and the equations of motion were integrated by 20 leap-frog algorithm with a time step of 2 fs. Finally, the atomic coordinates were recorded to the 21 22 trajectory file every 0.5 ps for later analysis.

3. Results and Discussion

3.1.Virtual screening and molecular docking

Considering the structural similarity with DHM as a representative inhibitor for αSN aggregation,
8609 compounds were obtained from PubChem database. The obtained compounds were filtered
using Lipinski's rule of five considering their Hydrogen bonding capacity, molecular weight, and
calculated log *P* as well as good TPSA. Finally, 314 out of 8609 compounds were selected as
potential satisfied drug with possibility of good absorption or permeability through the BBB.

The previously published experimental results suggest that IDPs remain disordered in their bound state [56]. Hence, the α SN monomer was chosen to investigate its affinity for DHM binding. A molecular docking study was carried out to find out the preferred location and conformation of DHM on aSN monomer. The docking pose of the most stable DHM-aSN complex is represented in Figure 1. The results reveal that DHM binds to the terminal part of aSN monomer's IDP domain which is the α SN binding site for rosmarinic acid [57]. The standard binding free energy (ΔG^0) of this interaction is about -5.8 kcal.mol⁻¹. The molecular complex system shows six H-bond interactions between DHM and Glu126, Met127, Pro128 and Glu130 residues of aSN. These H-bond interactions accompanied by hydrophobic interactions may have key roles in the stability of the system.







Figure 1. Docking pose of αSN-DHM complex. H-bond and hydrophobic interactions are represented as green dashed
 lines and red curves, respectively.



is very close to the obtained values for polyphenols of *Ocimum sanctum* (OS) extract which its
 inhibitory effect on αSN aggregation has been studied, before [57].

Moreover, the calculated log P value of this molecule is about 2.4 that makes it as a good BBB 3 permeable drug. Figure 2 represents the docking pose of the most stable complex of the selected 4 ligand and aSN monomer. Analysis of the docking results reveals that there are three H-bond 5 6 interactions between the ligand and Glu126, Pro128 and Ser129 residues of aSN. All binding energies and key residues involved in the interactions of DHM, candidate molecule and the other 7 first 21 screened compounds with the highest binding energies, with aSN monomer are 8 summarized in Table 1. These results revealed that H-bond, hydrophobic and π - π interactions have 9 dominant roles in binding of candidate molecules to aSN monomer. 10




Figure 2. Docking pose of the most stable complex of the selected ligand and αSN monomer. H-bond and hydrophobic
 interactions are represented as green dashed lines and red curves, respectively.

- 1 Table 1. Binding energies and key residues involved in the interactions of DHM (and the first 22 screened compounds
- 2 with the highest binding energies) and α SN monomer.

			Residues involved in:				
Rank	Name or PubChem ID	Binding Energy/kcal.mol ⁻¹	H-bond interactions	Hydrophobic interactions	π-π interactions		
-	DHM	-5.8	Glu126, Met127, Pro128, Glu130	Gly 132, Tyr 136	-		
1	100968625	-7.1	Glu126, Pro128, Ser129	Glu 123, Ala 124, Tyr 125, Met 127	-		
2	6280229	-7.0	Glu 126	Tyr 125, Met 127, Ser 129, Glu 130, Gly 132, Ala 140	Tyr 136		
3	129825792	-6.9	Glu 126	Ser 129, Gly 132, Ala 140	Tyr 125, Tyr 136		
4	129905005	-6.8	Glu 126, Met 127	Ser 129, Glu 130, Gly 132, Tyr 136	Tyr 125		
5	5315126	-6.7	Glu 126, Pro 128	Tyr 125, Glu 130, Glu 131, Gly 132, Tyr 136	-		
5	5467201	-6.7	Glu 126	Met 127	Tyr 125, Tyr 136		
5	71313853	-6.7	-	Glu 126, Pro 128, Glu 130	Tyr 125		
5	90643991	-6.7	Pro 128	Glu 126, Glu 130, Glu 131, Gly 132, Tyr 136	-		
6	14427462	-6.5	Glu 126, Tyr 136	Tyr 125, Glu 126, Met 127, Pro 128, Glu 130, Gly 132	Tyr 136		
6	67984060	-6.5	-	Glu 123, Glu 126, Pro 128, Ser 129	-		
6	90643985	-6.5	Met 127	Glu 126, Ser 129, Glu 130, Gly 132, Tyr 136	Tyr 125		
6	90643986	-6.5	-	Glu 126, Gly 132, Tyr 136	Tyr 125		
6	90643987	-6.5	Glu 126	Tyr 125, Ser 129, Gly 132, Tyr 136	-		
6	129825797	-6.5	Glu 126	Ser 129, Glu 130, Gly 132, Tyr 136	-		
6	129904975	-6.5	Met 127	Glu 126, Ser 129, Glu 130, Gly 132, Tyr 136	Tyr 125		
7	5315125	-6.4	Glu 126	Tyr 125, Glu 130, Gly 132, Tyr 136	-		
7	14427460	-6.4	Pro 128	Tyr 125, Met 127, Glu 130, Glu 131, Gly 132	Tyr 136		
7	23630406	-6.4	-	Glu 126, Ser 129, Glu 130, Glu 131, Tyr 136	-		
8	580166	-6.3	-	Glu 126, Ser 129, Glu 131	Tyr 125		
8	13349170	-6.3	-	Tyr 125	-		
8	13834128	-6.3	Met 127	Tyr 125, Glu 126, Pro 128, Glu 131	-		
8	18542127	-6.3	-	Tyr 125, Glu 126, Glu 130, Gly 132, Asp 135	-		

4 *3.2.MD simulation*

The interactions between ten molecules of the selected ligand (PubChem ID: 100968625) and a 5 α SN trimer was investigated using MD simulations method. The selected ligand (Figure S2) 6 contains a carbonyl group, two ether oxygen atoms, and five hydroxyl groups that can interact with 7 8 aSN via H-bond interaction. This makes a total of 8 possible H-bond sites for each ligand 9 molecule. Therefore, the total number of H-bonds formed between the α SN trimer and the ten ligand molecules was calculated and shown in Figure 3. Analysis of the results showed that H-10 11 bonds were formed between the aSN trimer and ligands, rapidly after few ns of MD simulation trajectory and their number increased to about 20 at around 30 ns and fluctuated around this mean 12 13 value until the end (about 2 H-bonds per ligand molecule). Figure 3b shows the representative structure of αSN and one of the ligands molecules interacting by H-bond interactions. It shows
that there was a H-bond interaction between hydrogen atom of the hydroxyl group of the ligand
and an oxygen atom of the carboxyl group of the side chain of the residue Glu57. Same interaction
has been reported for the interaction of DHM molecules with αSN trimer [34]. At the same time,
there was another hydrogen bond between the same ligand and the amide group of residue Glu120.





Figure 3. Interaction of the selected ligand (PubChem ID: 100968625) with the α SN timer. (a) Total number of hydrogen bonds between the α SN trimer and the ten ligand molecules during 100 ns of MD simulation. (b) Binding conformation between residues in the α SN trimer and one of the ligand molecules at the end of trajectory. The blue solid lines represent the H-bonds. Glu residues have been shown as pink ball & stick representation.

10

This observation is completely in agreement with the docking results and proves the key role of H-bond interactions in the stability of inhibitor- α SN complex. Furthermore, the previously published results have confirmed that H-bond interactions have important role in the interaction of their suggested inhibitors and α SN protein [21, 34, 57, 58]. The compactness of α SN trimer during the MD simulations (in the presence and absence of the selected compound) is an important factor to study the inhibitory effect of the candidate drug and conformational changes of the protein trimer during its interaction with it. Therefore, the radius of gyration (R_g) of the α SN trimer was evaluated as an index of protein structural compactness. Figure 4 shows that the R_g of α SN trimer in the presence of the selected compound increased in comparison to the case without the compound indicating the less compact structure of α SN trimer (Figure 4). The average values of R_g are about 2.03 and 2.11 nm for free α SN and its complex with 10 molecules of the candidate drug, respectively. This observation proves that the compound destabilizes the compact structure of α SN trimer.



7

Figure 4. Time dependence of the radius of gyration (Rg) for αSN trimer during the simulation, in the absence and
 presence of inhibitor.

10

To evaluate the mobility of the residues of αSN trimer, the root mean square fluctuations (RMSF)
of the residues of protein aggregate in the absence and presence of inhibitor were analyzed and
presented in Figure 5.







Figure 5. RMSF values of residues of αSN trimer during the 100 ns of simulation time, in the absence and presence
 of the inhibitor. (Chain I: residues 1-63; Chain II: residues 64-126 and Chain III: residues 127-189).

The results of the RMSF analysis indicate that all the residues of aSN trimer show higher 5 6 fluctuations in the presence of inhibitor molecules in comparison to the state without inhibitors. This observation is in consistency with the R_g results and could be another evidence about good 7 inhibitory effect of the selected compound as new inhibitor of aSN aggregation. The middle chain 8 9 (chain II in figure 5) of the α SN trimer has been surrounded between two other chains and is not accessible for the inhibitor molecules as much as two other chains. This protection causes its less 10 fluctuations in comparison to the chains I and III of the protein trimer in both states (in the presence 11 and absence of the inhibitors). 12

13 Figure 6 represents that during 100 ns of MD simulation trajectory, most of the inhibitor molecules 14 associate in N-terminal of the protein trimer that causes higher fluctuation of this part in three 15 chains of α SN trimer as it is clear in Figure 5. In the presence of the inhibitor, the N-terminal fluctuations of the three chains are about 14%, 15% and 18% higher than C-terminal for Chains I 16 to III, respectively. However, the maximum RMSF difference between the N- and C-terminal in 17 18 the absence of the inhibitor would be only about 7% (for chain I). In other words, the interaction 19 of inhibitor molecules with a SN chains weakens the intermolecular interactions between the Nterminal residues of the protein trimer and increase the fluctuations of the residues in this part of 20

1 the protein. Furthermore, one inhibitor molecule inserts into the interspace between two chains of 2 the α SN trimer, which would disturb the intermolecular interactions between the chains. To prove 3 this claim, the distance between the C α atoms of Glu57 of chain I and Glu120 of chain II was 4 calculated as shown in Figure 7. The average distance in the presence of inhibitor was about 12 Å 5 after 20 ns, while the distance in the α SN trimer in water was nearly 5 Å during the entire 6 simulation time. Therefore, insertion of the inhibitor molecule inside the inner space of the α SN 7 chains caused a loss of contact between two chains and disrupted their initial ordered structure.



9 Figure 6. Configuration of the ligand molecules around αSN trimer during 100 ns of MD simulation.

10




Figure 7. Change of Glu57-Glu120 distance in chains I and II of αSN trimer during the simulation, in the absence
 and presence of inhibitor.

1

5

6

4. Conclusion

In this study, we built a library of compounds with similar structure of Dihydromyricetin (DHM; 7 a natural flavonoid with inhibitory effect on aSN fibrillogenesis). Lipinski's "Rule of five" and 8 TPSA screenings were used to select the drug like compounds. Moreover, binding free energy and 9 10 binding modes of the filtered compounds were investigated using in silico virtual screening method. The analysis of the molecular docking calculations showed that the compound with 11 PubChem ID of 100968625 has the highest affinity for binding to α SN monomer ($\Delta G^{0}_{\text{binding}} = -7.1$ 12 kcal.mol⁻¹) among the other candidates. Its high binding affinity for α SN suggested that this 13 compound could be considered as an inhibitor for α SN aggregation with higher efficiency than 14 DHM and some of the other previously suggested antiPD drugs. The behavior of α SN trimer in 15 the presence of the selected candidate was further analyzed using molecular dynamics (MD) 16 simulation method. Analysis of MD trajectories showed that H-bond interactions between the 17 hydroxyl groups of the ligand molecules with side chains of the residues in aSN trimer could 18 19 destabilize the compact structure of aSN trimer. On the other hand, most of the inhibitor molecules

1	associate in N-terminal of the protein trimer and cause 100% increasing of fluctuations for the
2	residues in N-terminal of the trimer structure. Also, investigation of R_g of the α SN trimer showed
3	that the inhibitor molecules decrease the compactness of protein structure for about 4% in
4	comparison to the protein free state in water. Furthermore, penetration of one inhibitor molecule
5	into the interspace of two protein chains, disturbed the ordered structure of the αSN filament,
6	weakened the intermolecular interactions between the protein chains and increased their distance.
7	In conclusion, our study revealed the inhibitory effect of selected ligand (PubChem
8	ID=100968625) on α SN fibrillogenesis. Eventually, we believe that this study will shed the lights
9	on finding of potentially active compounds against the α SN aggregation. We also confirm that it
10	is necessary to do further in vitro and in vivo investigations for developing potent drug inhibitors
11	of α SN fibrillogenesis for the treatment of PD and similar diseases.
12	
13	
14	
15	
16	
17	
18	
19	Acknowledgments
20	M.S. is grateful to the French Agence Nationale de la Recherche (Grant: ANR-BIOLUM ANR-

21 16-CE29-0013).

1 References:

- 2 [1]. Poewe, W., et al., *Parkinson disease*. Nature reviews Disease primers, 2017. 3(1): p. 121.DOI: https://doi.org/10.1038/nrdp.2017.13.
- 4 [2]. Lewy, F.H., *Paralysis agitans. I.* Pathologische anatomie. Handbuch der neurologie, 1912.
- 5 [3]. Xu, L. and J. Pu, Alpha-synuclein in Parkinson's disease: from pathogenetic dysfunction
- *to potential clinical application*. Parkinson's Disease, 2016. 2016.DOI:
 https://doi.org/10.1155/2016/1720621.
- 8 [4]. Deleersnijder, A., et al., *The remarkable conformational plasticity of alpha-synuclein:*9 *blessing or curse?* Trends in molecular medicine, 2013. 19(6): p. 368-377.DOI:
 10 https://doi.org/10.1016/j.molmed.2013.04.002.
- 11 [5]. Mehra, S., S. Sahay, and S.K. Maji, α-Synuclein misfolding and aggregation: Implications
 in Parkinson's disease pathogenesis. Biochimica et Biophysica Acta (BBA)-Proteins and
 Proteomics, 2019. 1867(10): p. 890-908.DOI:

14 https://doi.org/10.1016/j.bbapap.2019.03.001.

- 15 [6]. Breydo, L., J.W. Wu, and V.N. Uversky, α-Synuclein misfolding and Parkinson's disease.
- 16 Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2012. 1822(2): p. 261-
- 17 285.DOI: <u>https://doi.org/10.1016/j.bbadis.2011.10.002</u>.
- 18 [7]. Theillet, F.-X., et al., *Structural disorder of monomeric α-synuclein persists in mammalian*
- 19 *cells*. Nature, 2016. **530**(7588): p. 45-50.DOI: <u>https://doi.org/10.1038/nature16531</u>.
- 20 [8]. Bartels, T., J.G. Choi, and D.J. Selkoe, α-Synuclein occurs physiologically as a helically
- folded tetramer that resists aggregation. Nature, 2011. 477(7362): p. 107-110.DOI:
- 22 <u>https://doi.org/10.1038/nature10324</u>.

1	[9].	Wang, W., et al., A soluble α -synuclein construct forms a dynamic tetramer. Proceedings
2		of the National Academy of Sciences, 2011. 108(43): p. 17797-17802.DOI:
3		https://doi.org/10.1073/pnas.1113260108.
4	[10].	Burré, J., et al., Properties of native brain α-synuclein. Nature, 2013. 498(7453): p. E4-
5		E6.DOI: https://doi.org/10.1038/nature12125.
6	[11].	Winner, B., et al., In vivo demonstration that α -synuclein oligomers are toxic. Proceedings
7		of the National Academy of Sciences, 2011. 108(10): p. 4194-4199.DOI:
8		https://doi.org/10.1073/pnas.1100976108.
9	[12].	Ma, L., et al., Non-polyphenolic natural inhibitors of amyloid aggregation. European
10		journal of medicinal chemistry, 2020. 192 : p. 112197.DOI:
11		https://doi.org/10.1016/j.ejmech.2020.112197.
12	[13].	Sangwan, S., et al., Inhibition of synucleinopathic seeding by rationally designed
13		inhibitors. Elife, 2020. 9: p. e46775.DOI: https://doi.org/10.7554/eLife.46775.
14	[14].	Chakraborty, A., S. Brauer, and A. Diwan, A review of possible therapies for Parkinson's
15		disease. Journal of Clinical Neuroscience, 2020. 76: p. 1-4.
16	[15].	Haddad, F., et al., Dopamine and levodopa prodrugs for the treatment of Parkinson's
17		disease. Molecules, 2018. 23(1): p. 40.
18	[16].	Stoker, T.B., K.M. Torsney, and R.A. Barker, <u>https://doi.org/10.3389/fnins.2018.00693</u> .
19		Frontiers in neuroscience, 2018. 12: p. 693.
20	[17].	Carrera, I. and R. Cacabelos, Current drugs and potential future neuroprotective
21		compounds for Parkinson's disease. Current neuropharmacology, 2019. 17(3): p. 295-306.

1	[18].	El-Agnaf, O.M., et al., A strategy for designing inhibitors of α -synuclein aggregation and						
2		toxicity as a novel treatment for Parkinson's disease and related disorders. The FASEB						
3		journal, 2004. 18(11): p. 1315-1317.DOI: https://doi.org/10.1096/fj.03-1346fje.						
4	[19].	Nagai, Y., et al., Inhibition of polyglutamine protein aggregation and cell death by novel						
5		peptides identified by phage display screening. Journal of Biological Chemistry, 2000.						
6		275 (14): p. 10437-10442.DOI: <u>https://doi.org/10.1074/jbc.275.14.10437</u> .						
7	[20].	Vittorio, S., et al., Rational design of small molecules able to inhibit α -synuclein amyloid						
8		aggregation for the treatment of Parkinson's disease. Journal of Enzyme Inhibition and						
9		Medicinal Chemistry, 2020. 35 (1): p. 1727-1735.DOI:						
10		https://doi.org/10.1080/14756366.2020.1816999.						
11	[21].	Jafaripour, S.S., et al., In silico drug repositioning of FDA-approved drugs to predict new						
12		inhibitors for alpha-synuclein aggregation. Computational Biology and Chemistry, 2020.						
13		88 : p. 107308.						
14	[22].	van Acker, F.A., et al., Flavonoids can replace α -tocopherol as an antioxidant. FEBS						
15		letters, 2000. 473(2): p. 145-148.DOI: <u>https://doi.org/10.1016/S0014-5793(00)01517-9</u> .						
16	[23].	Yu, J., et al., Antioxidant activity of citrus limonoids, flavonoids, and coumarins. Journal						
17		of agricultural and food chemistry, 2005. 53(6): p. 2009-2014.DOI:						
18		https://doi.org/10.1021/jf0484632.						
19	[24].	Kawaii, S., et al., Quantitation of flavonoid constituents in citrus fruits. Journal of						
20		Agricultural and Food Chemistry, 1999. 47(9): p. 3565-3571.DOI:						
21		https://doi.org/10.1021/jf990153+.						

22 [25]. Pszczola, D., Natural colors: pigments of imagination. Food technology (USA), 1998.

- [26]. Cooray, H.C., et al., <u>https://doi.org/10.1016/j.bbrc.2004.03.040</u>. Biochemical and
 biophysical research communications, 2004. **317**(1): p. 269-275.
- [27]. Khosravi, I. and M. Sahihi, *Computational Studies on the Interaction of Arctiin and Liquiritin With β-lactoglobulin*. Journal of Macromolecular Science, Part B, 2014. 53(9):
- 5 p. 1591-1600.DOI: <u>https://doi.org/10.1080/00222348.2014.946844</u>.
- [28]. Sahihi, M., *In-silico study on the interaction of saffron ligands and beta-lactoglobulin by molecular dynamics and molecular docking approach*. Journal of Macromolecular
 Science, Part B, 2016. 55(1): p. 73-84.DOI:
 https://doi.org/10.1080/00222348.2015.1125066.
- IO [29]. Sahihi, M. and Y. Ghayeb, *Binding of biguanides to β-lactoglobulin: molecular-docking and molecular dynamics simulation studies.* Chemical Papers, 2014. 68(11): p. 1601 1607.DOI: https://doi.org/10.2478/s11696-014-0598-7.
- [30]. Williams, R.J., J.P. Spencer, and C. Rice-Evans, *Flavonoids: antioxidants or signalling molecules?* Free radical biology and medicine, 2004. 36(7): p. 838-849.DOI: https://doi.org/10.1016/j.freeradbiomed.2004.01.001.
- 16 [31]. Sengupta, B., et al., Differential roles of 3-Hydroxyflavone and 7-Hydroxyflavone against
- 17 *nicotine-induced oxidative stress in rat renal proximal tubule cells.* PloS one, 2017. **12**(6):
- 18 p. e0179777.DOI: <u>https://doi.org/10.1371/journal.pone.0179777</u>.
- 19 [32]. Murakami, T., et al., *Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis*20 grossedentata, and ampelopsin. Biofactors, 2004. 21(1-4): p. 175-178.
- 21 [33]. Kou, X., et al., Ampelopsin attenuates 6-OHDA-induced neurotoxicity by regulating GSK-
- 22 *3β/NRF2/ARE signalling*. Journal of functional foods, 2015. **19**: p. 765-774.DOI:
 23 https://doi.org/10.1016/j.jff.2015.10.010.

1	[34].	Jia, L., et al., Dihydromyricetin Inhibits a-Synuclein Aggregation, Disrupts Preformed
2		Fibrils, and Protects Neuronal Cells in Culture against Amyloid-Induced Cytotoxicity.
3		Journal of agricultural and food chemistry, 2019. 67(14): p. 3946-3955.DOI:
4		https://doi.org/10.1021/acs.jafc.9b00922.
5	[35].	Kim, S., et al., PubChem 2019 update: improved access to chemical data. Nucleic acids
6		research, 2019. 47(D1): p. D1102-D1109.DOI: https://doi.org/10.1093/nar/gky1033.
7	[36].	Mirza, S.B., et al., Discovery of selective dengue virus inhibitors using combination of
8		molecular fingerprint-based virtual screening protocols, structure-based pharmacophore
9		model development, molecular dynamics simulations and in vitro studies. Journal of
10		Molecular Graphics and Modelling, 2018. 79: p. 88-102.DOI:
11		https://doi.org/10.1016/j.jmgm.2017.10.010.
12	[37].	Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility
13		and permeability in drug discovery and development settings. Advanced drug delivery
14		reviews, 1997. 23(1-3): p. 3-25.DOI: <u>https://doi.org/10.1016/S0169-409X(96)00423-1</u> .
15	[38].	Mikitsh, J.L. and AM. Chacko, Pathways for small molecule delivery to the central
16		nervous system across the blood-brain barrier. Perspectives in medicinal chemistry, 2014.
17		6: p. PMC. S13384.DOI: https://doi.org/10.4137%2FPMC.S13384.
18	[39].	Jin, Z., et al., Structure-based virtual screening of influenza virus RNA polymerase
19		inhibitors from natural compounds: molecular dynamics simulation and MM-GBSA
20		calculation. Computational biology and chemistry, 2020. 85: p. 107241.
21	[40].	Ulmer, T.S., et al., Structure and dynamics of micelle-bound human α -synuclein. Journal
22		of Biological Chemistry, 2005. 280 (10): p. 9595-9603.DOI:
23		https://doi.org/10.1074/jbc.M411805200.

1	[41].	Vriend, G., WHAT IF: a molecular modeling and drug design program. Journal of
2		molecular graphics, 1990. 8(1): p. 52-56.DOI: <u>https://doi.org/10.1016/0263-</u>
3		<u>7855(90)80070-V</u> .
4	[42].	Berendsen, H.J., D. van der Spoel, and R. van Drunen, GROMACS: a message-passing
5		parallel molecular dynamics implementation. Computer physics communications, 1995.
6		91 (1-3): p. 43-56.DOI: <u>https://doi.org/10.1016/0010-4655(95)00042-E</u> .
7	[43].	Oostenbrink, C., et al., A biomolecular force field based on the free enthalpy of hydration
8		and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. Journal of
9		computational chemistry, 2004. 25 (13): p. 1656-1676.DOI:
10		https://doi.org/10.1002/jcc.20090.
11	[44].	Dallakyan, S. and A.J. Olson, Small-molecule library screening by docking with PyRx, in
12		Chemical biology. 2015, Springer. p. 243-250.
13	[45].	Frisch, M., et al., EM64L-Gaussian 09, Revision D. 01, Gaussian. Inc., Wallingford CT,
14		2013.
15	[46].	Trott, O. and A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking
16		with a new scoring function, efficient optimization, and multithreading. Journal of
17		computational chemistry, 2010. 31 (2): p. 455-461.DOI: <u>https://doi.org/10.1002/jcc.21334</u> .
18	[47].	Li, Y., et al., Amyloid fibril structure of α -synuclein determined by cryo-electron
19		<i>microscopy</i> . Cell research, 2018. 28 (9): p. 897-903.DOI: <u>https://doi.org/10.1038/s41422-</u>
20		<u>018-0075-x</u> .
21	[48].	Schüttelkopf, A.W. and D.M. Van Aalten, PRODRG: a tool for high-throughput
22		crystallography of protein-ligand complexes. Acta Crystallographica Section D:

 1
 Biological
 Crystallography,
 2004.
 60(8):
 p.
 1355-1363.DOI:


 2
 https://doi.org/10.1107/S0907444904011679.


 <

- [49]. Lemkul, J.A., W.J. Allen, and D.R. Bevan, *Practical considerations for building GROMOS-compatible small-molecule topologies*. Journal of chemical information and
 modeling, 2010. 50(12): p. 2221-2235.DOI: https://doi.org/10.1021/ci100335w.
- 6 [50]. Pullman, A., Intermolecular forces. Vol. 14. 2013: Springer Science & Business Media.
- [51]. Lemak, A. and N. Balabaev, *On the Berendsen thermostat*. Molecular Simulation, 1994.
 13(3): p. 177-187.DOI: https://doi.org/10.1080/08927029408021981.
- 9 [52]. Parrinello, M. and A. Rahman, Polymorphic transitions in single crystals: A new molecular
- *dynamics method.* Journal of Applied physics, 1981. **52**(12): p. 7182-7190.DOI:
 https://doi.org/10.1063/1.328693.
- 12 [53]. Rahman, A. and F.H. Stillinger, *Molecular dynamics study of liquid water*. The Journal of
- 13 Chemical Physics, 1971. **55**(7): p. 3336-3359.DOI: <u>https://doi.org/10.1063/1.1676585</u>.
- 14 [54]. Darden, T., D. York, and L. Pedersen, Particle mesh Ewald: An N·log (N) method for
- 15 *Ewald sums in large systems*. The Journal of chemical physics, 1993. **98**(12): p. 10089-
- 16 10092.DOI: <u>https://doi.org/10.1063/1.464397</u>.
- 17 [55]. Essmann, U., et al., A smooth particle mesh Ewald method. The Journal of chemical
 18 physics, 1995. 103(19): p. 8577-8593.DOI: https://doi.org/10.1063/1.470117.
- 19 [56]. Liu, Z. and Y. Huang, *Advantages of proteins being disordered*. Protein Science, 2014.
 20 23(5): p. 539-550.DOI: <u>https://doi.org/10.1002/pro.2443</u>.
- 21 [57]. Meena, V.K., V. Kumar, and S. Karalia, <u>https://doi.org/10.1016/j.molliq.2021.116176</u>.
- 22 Journal of Molecular Liquids, 2021. **336**: p. 116176.

1	[58].	Jayaraj, R.L. and N. Elangovan, In silico identification of potent inhibitors of alpha-
2		synuclein aggregation and its in vivo evaluation using MPTP induced Parkinson mice
3		model. Biomedicine & Aging Pathology, 2014. 4(2): p. 147-152.
4		

1	Supporting Information
2	
3 4	Identification of new alpha-synuclein fibrillogenesis inhibitor using in silico structure-based virtual screening
5	
6	Mehdi Sahihi ^{1,2,*} , Fatma Gaci ² , Isabelle Navizet ²
7	¹ Roberval Laboratory, Université de Technologie de Compiègne, Alliance Sorbonne Université,
8	Compiègne, France
9	² MSME, Univ Gustave Eiffel, CNRS UMR 8208, Univ Paris Est Creteil,
10	F-77454 Marne-la-Vallée, France
11	
12	
13	
14	
15	
16	*Corresponding author:
17	Mehdi Sahihi
18	Tel: +33 (0) 6 24 67 38 28
19	Fax: +33 (0) 1 60 95 77 99
20	E-mail: mehdi.sahihi@gmail.com





2 Figure S2. Chemical structure of the selected ligand from PubChem free database using virtual

- 3 screening method (PubChem ID of 100968625; IUPAC name: 5,7-dihydroxy-2-[(2R,3R)-3-
- 4 (hydroxymethyl)-2-(4-hydroxyphenyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chromen-4-one).
- 5

PubChem ID	Optimized structure	Binding Energy/kcal.mol ⁻¹	PubChem ID	Optimized structure	Binding Energy/kcal.mol ⁻¹
		TPSA/Å ²			TPSA/Å ²
1880		-4.8	26034		-5.3
		70.67			109.36
88281		-5.0	159026		-5.6
		90.89			74.23
190366		-6.2	245874		-4.6
		116.84		૾ૡ૽ૡૼૢૡ૽૿ૻ૽ૢ૽ૡૻૡૢૡૻૡૡ ૻૢૡ	74.24
378687		-5.5	442410		-5.0
		68.91			86.99
580166		-6.3	639314		-6.0
	1.000 000 000 000 000000000000000000000	107.60			107.60
688853		-6.1	764011		-6.0
		90.89		9-3-3-3-4-3-	96.22


Table S1. PubChem chemical IDs, optimized structures and binding energies of 314 drug-like chemical compounds obtained from PubChem free database. 61 compounds with lower binding energies in comparison with DHM have been highlighted.

3512634	-5.3	5280343		-5.6
	86.99			131.35
5280445	-5.4	5280616	i i i i i i i i i i i i i i i i i i i	-5.9
	111.12			131.35
5280666	-5.2	5281604		-5.6
	100.13			120.36
5281605	-5.9	5281612		-5.4
	90.89			100.13
5281618	-5.1	5281638		-5.4
	79.90			131.35
5281642	-5.6	5281649		-4.9
	131.35			131.35
5281654	-5.4	5281665		-5.5
	120.36			111.12
5281676	-5.3	5281691		-5.7
	118.60			120.36

5281697		-5.6	5281699		-5.9
		111.12			120.36
5281701		-5.8	5281702		-5.1
		131.35			109.36
5281953		-5.0	5315125		-6.4
		129.59			111.12
5315126		-6.7	5315857		-4.4
		131.35			107.60
5318214		-5.6	5320287		-5.5
		100.13			109.36
5320428		-5.4	5320496		-4.8
		109.36			89.14
5320825		-5.5	5320945		-5.4
		127.83			109.36
5321864		-5.4	5322065		-5.5
		111.12			90.89

5323559		-4.2	5351234		-4.7
		118.60			89.14
5377945		-5.6	5378220		-5.5
		120.36			79.90
5379265		-5.1	5393164		-5.1
		98.37			111.12
5459196		-5.4	5464381		-4.9
		109.36		and the factors	89.14
5467201		-6.7	5481236	د مین دهنو دهنو مین در میندرد.	-5.3
		118.60			100.13
5481248		-5.4	5487855		-5.0
		118.60			109.36
5488150		-5.3	5488643		-5.0
		89.14			109.36

44258278		-5.3	5491448		-5.1
		120.36		3959-39-3-5-5-39-3 9-39-39-39-39-39-39-39-39-39-39-39-39-39	118.60
5496473		-5.6	5496476		-5.2
		109.36			98.37
5704578		-5.4	5748558		-4.4
		109.36			98.37
6280229	ాల్లె లైన్. సైల్లె లైన్. సైల్లె లైన్. జి. సై	-7.0	6452329		-5.7
		118.60			140.59
6477684		-6.0	6477685		-6.2
		90.89			111.12
7019535		-5.2	7330522		-5.0
		118.60			118.60
9888259		-4.6	9951473	2000 2000 2000 2000 2000 2000 2000	-5.2
		138.82			129.59
10020234		-5.5	10320814		-5.6
		109.36			107.60



10807220	-5.1	10861984	دوقود کود	-5.8
	109.36			108.38
10947972	 -5.3	10970376		-5.2
	94.46			87.38
11012936	-4.7	11247770		-4.8
	109.36		مېرى ئورى ئورى مېرى ئورى ئورى د ئورى د ئورى در يورى	134.68
11267045	-5.4	11300972		-5.4
	120.36			79.90
11347622	-5.6	12042311		-5.7
	131.35			127.44
12133313	-5.1	12214328		-5.7
	68.91			70.67
12214333	-5.2	12261165		-5.0
	68.91			68.91
12305312	-5.1	12314036		-5.7
	131.35			100.13

12359024	-5.9	12359025		-5.8
	111.12			111.12
12532439	-5.5	13259662		-5.0
	118.60			127.44
13349170	-6.3	13834089		-5.6
	68.91		3 − 4 5 3 − 4 5 3 − 4 5 - 4 5 − 4 − 4 − 5 − 4 5 − 4 5 - 5 − 4 5 − 4 − 5 − 6 − 6 5 − 6 5 - 5 − 4 5 − 5 − 5 − 6 − 6 5	116.84
13834127	-5.6	13834128	, 2	-6.3
	107.60		్ , ఉ _{చ్} ఉ _చ ారా ఉంద్రంగ్ 	107.60
13915678	-5.3	13916267		-5.0
	129.59			96.61
13942544	-5.3	13942545		-5.5
	96.61		ి తాత్తి చిత్తి చిత్తి చిత్తి ఎంత్ తోప్ ప్ తెల్లి చిత్తి త్వర్తి ప్రతి	87.38
13942681	-5.0	13964545		-5.7
	129.59			78.14
13964546	-4.8	13964547		-5.8
	78.14			89.14

13964548	• • • • • •	-5.8	13964549		-5.5
		89.14			89.14
10664985	and and the second	-5.9	13964550		-5.9
		109.36			100.13
14162696		-5.6	14234929		-4.8
		109.36			98.37
14259793		-5.1	14353344		-5.7
		87.38		³ °•°, °°, °°, °°, °°, °°, °°, °°, °°, °°,	76.00
14354990		-5.4	14427460		-6.4
		87.38			116.84
14794882		-5.4	15054680		-5.5
		96.22			66.76
15108682		-5.1	15222911		-5.1
		89.14			98.37
15227607		-5.6	15293760		-5.8
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	109.36			111.12

15379040		-5.6	15560536		-5.1
		100.13		من کې	98.37
15560612		-5.9	15614392		-5.2
		100.13			126.43
15661823		-5.4	15693661	 	-5.3
		111.12			89.14
15703606		-5.0	15814159		-5.2
	૾૱ૻૡૢૼૻૼૢૢૡૻૼૢૢૼૻૼૢ૽ૡૻૢૡૢ	86.99		ين من	89.14
16093656		-5.0	16662883		-4.6
		96.22			90.89
9549306		-5.6	18542127	Jacob Salar	-6.3
		124.29		3-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0	79.90
19049226		-5.2	19049238		-5.8
		118.60		్రత్తత్త్త్ ^{కార్య} త్త్రం త్రక్త	118.60
18778787		-4.8	19049246		-5.3
		109.36			129.59

19049277		-5.1	19065204	  	-5.7
		118.60		و من	115.44
19065213		-5.4	19065216	్రాలు సంగార్థులో సంగత్స్ సార్థులో సంగత్స్ సార్థులో సంగత్స్ సార్థులో సంగత్స్ సార్థులో సంగత్స్ సార్థులో సార్థులో సార్థు సార్థులో సార్థులో సార	-5.0
		115.44			78.14
19065246		-4.9	19358582		-5.8
		89.14		ja a a a a a a a a a a a a a a a a a a	115.44
19358620		-5.0	19890110		-5.2
		76.00			107.60
21158518		-5.8	21595562		-6.2
		111.12			107.60
21600688		-5.5	21633676		-5.2
		131.35			120.36
21676257		-5.0	21721829		-4.6
	ు తెల్లె తెల్లె పెల్లె ఎంత్లై తెల్లె పెల్లెలు	96.22			74.23

21636238	-5.1	21721836	نود محمد محد	-5.5
	74.23			94.46
21767017	-4.7	22324458	and a second	-4.6
	68.91			68.91
22339062	-6.0	23242592		-5.6
	131.35		د هې شوغې خو د د د د د د د د د د د د د د د د د د	107.60
23242593	-4.8	23247874		-4.9
	116.84			134.68
23259520	 -5.5	23320229		-5.7
	107.60			100.13
23630406	-6.4	24721675		-5.8
	100.13			131.35
25030204	-5.7	25189537		-6.0
	120.36			111.12
25189611	-5.5	25201972		-5.7
	111.12			113.95

25203524		-5.6	25267158	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	-6.2
		102.96			89.14
44258150		-6.1	44259518		-5.4
	a daga angaran Saga ang angaran Saga ang ang ang ang ang ang ang ang ang	137.43			129.59
44259511		-5.5	44259639		-5.5
		129.59			107.60
44259523		-5.0	5280343		-5.6
		118.60			131.35
44259638		-5.7	57381727		-5.9
		129.59		المركب والمحافظ والمح	109.36
44259903		-6.1	57402278		-5.5
	generation of the second se	120.36			120.36
44608108		-5.5	58076345		-5.6
	ాత్తి కారాత్రావా ప్రత్యాత్ని స్పాత్రావా త్ని ప్రత్యాత్ని స్ప	100.13			131.35
44608109		-5.5	44608113		-5.2
		100.13			89.14

44608260		-4.6	44608261		-5.7
		100.13			100.13
44608262		-5.3	44608263		-5.1
		100.13			100.13
44610309		-5.3	44610310		-5.5
		100.13		-g ³	100.13
44610311		-5.5	44610313	ه د. د. و ^{ره} وه	-5.1
		100.13	_	, , , , , , , , , , , , , , , , , , ,	100.13
44610314		-5.8	44610473	د و ^و و د	-6.1
		100.13			100.13
44610474		-5.2	44610475		-5.6
		100.13			100.13
44610476		-5.7	44610477		-4.8
		100.13			100.13
44610478		-5.9	44610479		-5.0
	**************************************	100.13		موضوعة من	100.13

46781386		-5.1	46878515		-5.4
		100.13			123.19
46878516		-4.9	46878517	ູ່ ອີມ ຄ	-4.9
		112.19			101.20
46878558		-5.8	46906036		-5.2
		134.18			134.18
49849634		-5.4	49849859		-6.0
	3 Jacob - Jaco	100.13			131.35
53819694		-5.7	53819695		-5.9
		129.59			129.59
54760989		-5.0	56929794		-5.3
		79.90			120.36
59918405		-4.7	59991307		-5.9
	د و من می مود در د من و مود و مرد د من و مرد	118.60			111.12
66684101	 پۇچى يىڭى	-5.1	67984060		-6.5
	૾ૡ૽૱ૡૼૢૡ૱ૡ૽ૡૡ૽ ૾ૡ૾૱ૻ૱ૢૡ૾ૢૡ૾ૡૡ૽	98.37		ు తిత్తాతాతాతాతించింది. పతిత్తారించింది. పతి తిత్రారించింది.	120.36

69211947		-5.8	69325736		-5.1
	ుత్తంతంతంతంతం సంత్ర సందంతం సత్ర సంగ్రామం	100.13			98.37
70231225		-5.7	71313853		-6.7
		131.35			100.13
71314865		-5.5	71414490		-5.7
		100.13			111.12
71600119	محمود موجود	-4.7	71723454		-5.7
		109.36			78.14
14427462		-6.5	14757915		-5.9
		126.07			116.84
70020252		-5.6	71723737		-5.4
		111.12		-9-9-9- -9-9-9- -9-9-9-9-9-9-9-9-9-9-9-	100.13
73897342	- دون في في د م في في في م	-5.0	86289526		-5.5
	میں۔حکر ^{مہر} کی طبق ہو میں۔حکو دختی ہو دی۔حکو ہو	89.14			113.95
71723456	د و هو هو د د و هو هو د	-5.6	71723458	ာင္ မ သူမိအုိခုိင္	-5.2
	ి ఉందించిందిందింది. సాత్ర సంత్రించిందింది. సాత్రి సంత్రించిందింది.	78.14		<u>, 3</u> , 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4,	78.14

76311605		-5.8	76327075	-6.1
	دونوند می محمد می می می از در از می	89.14		131.35
76330740		-5.5	85981660	-5.8
		111.12		131.35
88462991		-5.8	90657702	-5.4
		131.35		118.60
88494854		-5.3	89781809	-6.2
		129.59		120.36
90643985		-6.5	90643986	 -6.5
		120.36		 120.36
90643987		-6.5	90643991	-6.7
		120.36		120.36
91028282		-5.5	91069955	 -5.8
		127.44		131.35
91162275	and the second second	-6.0	91228926	 -5.5
		111.12		127.44

100985949		-6.1	100985950		-5.7
		128.18			128.18
100995351		-5.4	101064810	a de la de la de	-6.1
		79.90			109.36
100968625	5	-7.1	101064811	and the second	-6.0
		129.59			109.36
101566521		-5.7	101675226	مېشى يې يې مېشى د يې	-5.9
		137.43			120.36
101914779		-5.7	129646445		-5.7
		109.36			128.19
102276010		-5.2	102292606		-5.7
		100.13			137.43
118711942		-5.8	118711944		-4.7
		120.36			120.36
118712001		-5.5	118711943		-5.6
	33-84 - 45 - 45 - 45 - 45 - 45 - 45 - 45 -	109.36			120.36

118712002		-5.5	118712003		-5.4
	ي في المراجع ال المراجع المراجع المراجع المراجع المراجع	109.36		مي تقرير تقرير تقرير تقرير المراجع الم المراجع المراجع ا المراجع المراجع	109.36
123649972	34 3 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	-5.5	124202864		-5.6
		120.36			120.36
129648032		-5.8	129711975		-5.8
		131.35		**************************************	109.36
129713895		-5.7	129825762	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	-6.0
		131.35			129.59
129825792		-6.9	129825797		-6.5
		120.36			129.59
129852329		-5.7	129868619		-5.2
		109.36			135.95
129882434		-5.4	129904975		-6.5
	9-4-3-4-5-4-5-4-5-4-5-4-5-4-5-4-5-4-5-4-5	120.36		and a second s	120.36

130335262	-5.1	130335485		-4.9
	90.89			120.36
131831747	-5.6	131834556		-4.8
	131.35			120.36
131836638	-5.7	131837240	and a set a	-5.8
	140.59			100.13
131837242	-5.3	131837258		-4.7
	111.12			89.14
129905005	-6.8	131839469		-5.6
	120.36			100.13
134820127	 -5.4	134836277		-5.9
	73.50			129.59
137010076	-5.6	138112436		-4.6
	137.43			120.36
138112463	-5.9	139080697		-5.9
	120.36			109.36

139593046	-4.8 89.14	140279985	-5.7 127.44
141151974	-5.7 90.89	141256537	-5.5 109.36
141312957	-5.2 100.13	141806715	-5.8 100.13